Complicated Pericarditis: Understanding Risk Factors and Pathophysiology to Inform Imaging and Treatment

Journal of the American College of Cardiology

Volumn 68, Issue 21, 2016, Pages 2311-2328

  Cremer, Paul C ^a   Kumar, Arnav ^a   Kontzias, Apostolos ^a   Tan, Carmela D ^a   Rodriguez, E Rene ^a   Imazio, Massimo ^b   Klein, Allan L ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

autoimmune diseases; cardiovascular magnetic resonance imaging; colchicine; inflammasome; inflammation; pericardiectomy

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; COLCHICINE; CORTICOSTEROID; IMMUNOGLOBULIN; INFLAMMASOME; NONSTEROID ANTIINFLAMMATORY AGENT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; GLUCOCORTICOID;

AUTOIMMUNE DISEASE; CARDIOVASCULAR MAGNETIC RESONANCE; COMPARATIVE STUDY; CONSTRICTIVE PERICARDITIS; DISEASE ASSOCIATION; DISEASE COURSE; DRUG MEGADOSE; DRUG TARGETING; HISTOPATHOLOGY; HUMAN; IMAGING; MULTIMODALITY IMAGING; PATHOPHYSIOLOGY; PATIENT CARE; PATIENT SELECTION; PERICARDIECTOMY; PERICARDITIS; PERIODIC FEVER SYNDROME; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECURRENT DISEASE; RECURRENT FEVER; RELAPSE; REMISSION; REVIEW; RISK FACTOR; TREATMENT DURATION; CINE MAGNETIC RESONANCE IMAGING; GLOBAL HEALTH; INCIDENCE; PATHOLOGY; PERICARDIUM; PROCEDURES; SURVIVAL RATE; TRENDS; X-RAY COMPUTED TOMOGRAPHY;

GLOBAL HEALTH; GLUCOCORTICOIDS; HUMANS; INCIDENCE; MAGNETIC RESONANCE IMAGING, CINE; PERICARDIECTOMY; PERICARDITIS; PERICARDIUM; RISK FACTORS; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84997794987     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2016.07.785     Document Type: Review

References (95)

1. 1 Mozaffarian, D., Benjamin, E.J., Go, A.S., et al. for the American Heart Association Statistics Committee, Stroke Statistics Subcommittee. Heart disease and stroke statistics—2016 update: a report from the American Heart Association. Circulation 133 (2016), e38–e360.
2. 2 Imazio, M., Spodick, D.H., Brucato, A., et al. Controversial issues in the management of pericardial diseases. Circulation 121 (2010), 916–928.
3. 3 Imazio, M., Gaita, F., LeWinter, M., Evaluation and treatment of pericarditis: a systematic review. [erratum in JAMA 2015;314:1978] JAMA 314 (2015), 1498–1506.
4. 4 LeWinter, M.M., Clincal practice. Acute pericarditis. N Engl J Med 371 (2014), 2410–2416.
5. 5 Adler, Y., Charron, P., Imazio, M., et al. 2015 ESC guidelines for the diagnosis and management of pericardial diseases. Eur Heart J 36 (2015), 2921–2964.
6. 6 Imazio, M., Demichelis, B., Parrini, I., et al. Day-hospital treatment of acute pericarditis: a management program for outpatient therapy. J Am Coll Cardiol 43 (2004), 1042–1046.
7. 7 Imazio, M., Gaita, F., Diagnosis and treatment of pericarditis. Heart 101 (2015), 1159–1168.
8. 8 Klein, A.L., Abbara, S., Agler, D.A., et al. American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with pericardial disease: endorsed by the Society for Cardiovascular Magnetic Resonance and Society of Cardiovascular Computed Tomography. J Am Soc Echocardiogr 26 (2013), 965–1012.e15.
9. 9 Cosyns, B., Plein, S., Nihoyanopoulos, P., et al. European Association of Cardiovascular Imaging (EACVI) position paper: multimodality imaging in pericardial disease. Eur Heart J Cardiovasc Imaging 16 (2015), 12–31.
10. 10 Imazio, M., Bobbio, M., Cecchi, E., et al. Colchicine in addition to conventional therapy for acute pericarditis: results of the COlchicine for acute PEricarditis (COPE) Trial. Circulation 112 (2005), 2012–2016.
11. 11 Imazio, M., Bobbio, M., Cecchi, E., et al. Colchicine as first-choice therapy for recurrent pericarditis: results of the CORE (COlchicine for REcurrent Pericarditis Trial). Arch Intern Med 165 (2005), 1987–1991.
12. 12 Imazio, M., Brucato, A., Cemin, R., et al., for the CORP (COlchicine for Recurrent Pericarditis) Investigators. Colchicine for Recurrent Pericarditis (CORP): a randomized trial. Ann Intern Med 155 (2011), 409–414.
13. 13 Mayosi, B.M., Burgess, L.J., Doubell, A.F., Tuberculous pericarditis. Circulation 112 (2005), 3608–3616.
14. 14 Mayosi, B.M., Ntsekhe, M., Bosch, J., et al., for the IMPI Trial Investigators. Prednisolone and Mycobacterium indicus pranii in tuberculous pericarditis. N Engl J Med 371 (2014), 1121–1130.
15. 15 Imazio, M., Hoit, B.D., Post-cardiac injury syndromes. An emerging cause of pericardial diseases. Int J Cardiol 168 (2013), 648–652.
16. 16 Gouriet, F., Levy, P.Y., Casalta, J.P., et al. Etiology of pericarditis in a prospective cohort of 1162 cases. Am J Med 128 (2015), 784.e1–784.e8.
17. 17 Imazio, M., Brucato, A., Doria, A., et al. Antinuclear antibodies in recurrent idiopathic pericarditis: prevalence and clinical significance. Int J Cardiol 136 (2009), 289–293.
18. 18 Prasad, M., Hermann, J., Gabriel, S.E., et al. Cardiorheumatology: cardiac involvement in systemic rheumatic disease. Nat Rev Cardiol 12 (2015), 168–176.
19. 19 Hoffman, M., Fried, M., Jabareen, F., et al. Anti-heart antibodies in postpericardiotomy syndrome: cause or epiphenomenon? A prospective, longitudinal pilot study. Autoimmunity 35 (2009), 241–245.
20. 20 Imazio, M., Brucato, A., Cemin, R., et al., for the ICAP Investigators. A randomized trial of colchicine for acute pericarditis. N Engl J Med 369 (2013), 1522–1528.
21. 21 Imazio, M., Belli, R., Brucato, A., et al. Efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2): a multicentre, double-blind, placebo-controlled, randomised trial. Lancet 383 (2014), 2232–2237.
22. 22 Shahar, A., Hod, H., Barabash, G.M., et al. Disappearance of a syndrome: Dressler's syndrome in the era of thrombolysis. Cardiology 85 (1994), 255–258.
23. 23 Imazio, M., Negro, A., Belli, R., et al. Frequency and prognostic significance of pericarditis following acute myocardial infarction treated by primary percutaneous coronary intervention. Am J Cardiol 103 (2009), 1525–1529.
24. 24 Imazio, M., Trinchero, R., Brucato, A., et al., for the COPPS Investigators. COlchicine for the Prevention of the Post-pericardiotomy Syndrome (COPPS): a multicentre, randomized, double-blind, placebo-controlled trial. Eur Heart J 31 (2010), 2749–2754.
25. 25 Imazio, M., Brucato, A., Ferrazzi, P., et al., for the COPPS-2 Investigators. Colchicine for prevention of postpericardiotomy syndrome and postoperative atrial fibrillation; the COPPS-2 randomized clinical trial. JAMA 312 (2014), 1016–1023.
26. 26 Syed, F.F., Schaff, H.V., Oh, J.K., Constrictive pericarditis—a curable diastolic heart failure. Nat Rev Cardiol 11 (2014), 530–544.
27. 27 Imazio, M., Brucato, A., Maestroni, S., et al. Risk of constrictive pericarditis after acute pericarditis. Circulation 124 (2011), 1270–1275.
28. 28 Haley, J.H., Tajik, A.J., Danielson, G.K., et al. Transient constrictive pericarditis: causes and natural history. J Am Coll Cardiol 43 (2004), 271–275.
29. 29 Kytö, V., Sipilä, J., Rautava, P., Clinical profile and influences on outcomes in patients hospitalized for acute pericarditis. Circulation 130 (2014), 1601–1606.
30. 30 Imazio, M., Brucato, A., Barbieri, A., et al. Good prognosis for pericarditis with and without myocardial involvement: results from a multicenter, prospective cohort study. Circulation 128 (2013), 42–49.
31. 31 Imazio, M., Cecchi, E., Demichelis, B., et al. Myopericarditis versus viral or idiopathic acute pericarditis. Heart 94 (2008), 498–501.
32. 32 Imazio, M., Cecchi, E., Demichelis, B., et al. Indicators of poor prognosis of acute pericarditis. Circulation 115 (2007), 2739–2744.
33. 33 Imazio, M., Brucato, A., Maestroni, S., et al. Prevalence of C-reactive protein elevation and time course of normalization in acute pericarditis: implications for the diagnosis, therapy, and prognosis of pericarditis. Circulation 123 (2011), 1092–1097.
34. 34 Bertog, S.C., Thambidorai, S.K., Parakh, K., et al. Constrictive pericarditis: etiology and cause-specific survival after pericardiectomy. J Am Coll Cardiol 43 (2004), 1445–1452.
35. 35 Douglas, P.S., Garcia, M.J., Haines, D.E., et al. ACCF/ASE/AHA/ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 appropriate use criteria for echocardiography: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Society of Echocardiography, American Heart Association, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Critical Care Medicine, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. J Am Coll Cardiol 57 (2011), 1126–1166.
36. 36 Kramer, C.M., Barkhausen, J., Flamm, S.D., et al., for the Society for Cardiovascular Magnetic Resonance Board of Trustees. Task Force on Standardized Cardiovascular Magnetic Resonance. Standardized cardiovascular magnetic resonance (CMR) protocols 2013 update. J Cardiovasc Magn Reson, 15, 2013, 91.
37. 37 Cremer, P.C., Kwon, D.H., Multimodality imaging of pericardial disease. Curr Cardiol Rep, 17, 2015, 24.
38. 38 Bogaert, J., Francone, M., Pericardial disease: value of CT and MR imaging. Radiology 267 (2013), 340–356.
39. 39 Hatle, L.K., Appleton, C.P., Popp, R.L., Differentiation of constrictive pericarditis and restrictive cardiomyopathy by Doppler echocardiography. Circulation 79 (1989), 357–370.
40. 40 Garcia, M.J., Rodriguez, L., Ares, M., et al. Differentiation of constrictive pericarditis from restrictive cardiomyopathy: assessment of left ventricular diastolic velocities in longitudinal axis by Doppler tissue imaging. J Am Coll Cardiol 27 (1996), 108–114.
41. 41 Reuss, C.S., Wilansky, S.M., Lester, S.J., et al. Using mitral ‘annulus reversus’ to diagnose constrictive pericarditis. Eur J Echocardiogr 10 (2009), 372–375.
42. 42 Kusunose, K., Dahiya, A., Popović, Z.B., et al. Biventricular mechanics in constrictive pericarditis comparison with restrictive cardiomyopathy and impact of pericardiectomy. Circ Cardiovasc Imaging 6 (2013), 399–406.
43. 43 Sengupta, P.P., Krishnamoorthy, V.K., Abhayaratna, W.P., et al. Disparate patterns of left ventricular mechanics differentiate constrictive pericarditis from restrictive cardiomyopathy. J Am Coll Cardiol Img 1 (2008), 29–38.
44. 44 Welch, T.D., Ling, L.H., Espinosa, R.E., et al. Echocardiographic diagnosis of constrictive pericarditis: Mayo Clinic criteria. Circ Cardiovasc Imaging 7 (2014), 526–534.
45. 45 Francone, M., Dymarkowski, S., Kalantzi, M., et al. Assessment of ventricular coupling with real-time cine MRI and its value to differentiate constrictive pericarditis from restrictive cardiomyopathy. Eur Radiol 16 (2006), 944–951.
46. 46 Bolen, M.A., Rajiah, P., Kusunose, K., et al. Cardiac MR imaging in constrictive pericarditis: multiparametric assessment in patients with surgically proven constriction. Int J Cardiovasc Imaging 31 (2015), 859–866.
47. 47 Ferrans, V.J., Ishihara, T., Roberts, W.C., Anatomy of the pericardium. Spodick, D.H., (eds.) Pericardial Disease, 1982, Raven Press, New York, 15–39.
48. 48 Bogaert, J., Francone, M., Cardiovascular magnetic resonance in pericardial diseases. J Cardiovasc Magn Reson, 11, 2009, 14.
49. 49 Cremer, P.C., Tariq, M.U., Karwa, A., et al. Quantitative assessment of pericardial delayed hyperenhancement predicts clinical improvement in patients with constrictive pericarditis treated with anti-inflammatory therapy. Circ Cardiovasc Imaging, 8, 2015, e003125.
50. 50 Young, P.M., Glockner, J.F., Williamson, E.E., et al. MR imaging findings in 76 consecutive surgically proven cases of pericardial disease with CT and pathologic correlation. Int J Cardiovasc Imaging 28 (2011), 1099–1109.
51. 51 Taylor, A.M., Dymarkowski, S., Verbeken, E.K., et al. Detection of pericardial inflammation with late-enhancement cardiac magnetic resonance imaging: initial results. Eur Radiol 16 (2006), 569–574.
52. 52 Mewton, N., Liu, C.Y., Croisille, P., et al. Assessment of myocardial fibrosis with cardiovascular magnetic resonance. J Am Coll Cardiol 57 (2011), 891–903.
53. 53 Zurick, A.O., Bolen, M.A., Kwon, D.H., et al. Pericardial delayed hyperenhancement with CMR imaging in patients with constrictive pericarditis undergoing surgical pericardiectomy; a case series with histopathologic correlation. J Am Coll Cardiol Img 4 (2011), 1180–1191.
54. 54 Imazio, M., Demichelis, B., Parrini, I., et al. Recurrent pain without objective evidence of disease in patients with previous idiopathic or viral acute pericarditis. Am J Cardiol 94 (2004), 973–975.
55. 55 Alraies, M.C., AlJaroudi, W., Yarmohammadi, H., et al. Usefulness of cardiac magnetic resonance-guided management in patients with recurrent pericarditis. Am J Cardiol 115 (2015), 542–547.
56. 56 Feng, D., Glockner, J., Kim, K., et al. Cardiac magnetic resonance imaging pericardial late gadolinium enhancement and elevated inflammatory markers can predict the reversibility of constrictive pericarditis after antiinflammatory medical therapy: a pilot study. Circulation 124 (2011), 1830–1837.
57. 57 Imazio, M., Idiopathic recurrent pericarditis as an immune-mediated disease: current insights into pathogenesis and emerging treatment options. Exp Rev Clin Immunol 10 (2014), 1487–1492.
58. 58 Artom, G., Koren-Morag, N., Spodick, D.H., et al. Pretreatment with corticosteroids attenuates the efficacy of colchicine in preventing recurrent pericarditis: a multi-centre all-case analysis. Eur Heart J 26 (2005), 723–727.
59. 59 Cusick, M.F., Libbey, J.E., Fujinami, R.S., Molecular mimicry as a mechanism of autoimmune disease. Clin Rev Allerg Immunol 42 (2012), 102–111.
60. 60 Sfriso, P., Ghirardello, A., Botsios, C., et al. Infections and autoimmunity: the multifaceted relationship. J Leukoc Biol 87 (2010), 385–395.
61. 61 Park, H., Bourla, A.B., Kastner, D.L., et al. Lighting the fires within: the cell biology of autoinflammatory diseases. Nat Rev Immunol 12 (2012), 570–580.
62. 62 van Kempen, T.S., Wenink, M.H., Leijten, E.F.A., et al. Perception of self: distinguishing autoimmunity from autoinflammation. Nat Rev Rheumatol 11 (2015), 483–492.
63. 63 Martinon, F., Pétrilli, V., Mayor, A., et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440 (2006), 237–241.
64. 64 Muruve, D.A., Pétrilli, V., Zaiss, A.K., et al. The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response. Nature 452 (2008), 103–107.
65. 65 Duewell, P., Kono, H., Rayner, K.J., et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464 (2010), 1357–1361.
66. 66 McDermott, M.F., Aksentievich, I., Galon, J., et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 97 (1999), 133–144.
67. 67 Lachmann, H.J., Papa, R., Gerhold, K., et al. for the Paediatric Rheumatology International Trials Organisation (PRINTO), the EUROTRAPS and the Eurofever Project. The phenotype of TNF receptor-associated autoinflammatory syndrome (TRAPS) at presentation: a series of 158 cases from the Eurofever/EUROTRAPS international registry. Ann Rheum Dis 73 (2014), 2160–2167.
68. 68 Cantarini, L., Lucherini, O.M., Baldari, C.T., et al. Familial clustering of recurrent pericarditis may disclose tumour necrosis factor receptor-associated periodic syndrome. Clin Exp Rheumatol 28 (2010), 405–407.
69. 69 Cantarini, L., Rigante, D., Merlini, G., et al. The expanding spectrum of low-penetrance TNFRSF1A gene variants in adults presenting with recurrent inflammatory attacks: clinical manifestations and long-term follow-up. Sem Arthritis Rheum 43 (2014), 818–823.
70. 70 Booty, M.G., Chae, J.J., Masters, S.L., et al. Familial Mediterranean fever with a single MEFV mutation: where is the second hit?. Arthritis Rheum 60 (2009), 1851–1861.
71. 71 Yu, J.W., Wu, J., Zhang, Z., et al. Cryopyrin and pyrin activate caspase-1, but not NF-κB, via ASC oligomerization. Cell Death Diff 13 (2006), 236–249.
72. 72 Ozen, S., Demirkaya, E., Amaryan, G., et al. for the Paediatric Rheumatology International Trials Organisation (PRINTO), Eurofever Project. Results from a multicentre international registry of familial Mediterranean fever: impact of environment on the expression of a monogenic disease in children. Ann Rheum Disease 73 (2014), 662–667.
73. 73 Leung, Y.Y., Hui, L.L.Y., Kraus, V.B., Colchicine—update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum 45 (2015), 341–350.
74. 74 Miner, J.J., Kim, A.H.J., Cardiac manifestations of systemic lupus erythematosus. Rheum Disease Clin North Amer 40 (2014), 51–60.
75. 75 Doria, A., Iaccarino, L., Sarzi-Puttini, P., et al. Cardiac involvement in systemic lupus erythematosus. Lupus 14 (2005), 683–686.
76. 76 Voskuyl, A.E., The heart and cardiovascular manifestations in rheumatoid arthritis. Rheumatology (Oxford) 45:Suppl 4 (2006), iv4–iv7.
77. 77 Nathan, C., Neutrophils and immunity: challenges and opportunities. Nat Rev Immunol 6 (2006), 173–182.
78. 78 Yang, C.A., Chiang, B.L., Inflammasomes and human autoimmunity: a comprehensive review. J Autoimmun 61 (2015), 1–8.
79. 79 Horneffer, P.J., Miller, R.H., Pearson, T.A., et al. The effective treatment of postpericardiotomy syndrome after cardiac operations. A randomized placebo-controlled trial. J Thorac Cardiovasc Surg 100 (1990), 292–296.
80. 80 Lotrionte, M., Biondi-Zoccai, G., Imazio, M., et al. International collaborative systematic review of controlled clinical trials on pharmacologic treatments for acute pericarditis and its recurrences. Am Heart J 160 (2010), 662–670.
81. 81 Imazio, M., Colchicine for pericarditis. Trends Cardiovasc Med 25 (2015), 129–136.
82. 82 Imazio, M., Gaita, F., Colchicine for cardiovascular medicine. Future Cardiol 12 (2016), 9–16.
83. 83 Rodríguez de la Serna, A., Guindo Soldevila, J., Martí Claramunt, V., et al. Colchicine for recurrent pericarditis. Lancet, 2, 1987, 1517.
84. 84 Verma, S., Eikelboom, J.W., Nidorf, S.M., et al. Colchicine in cardiac disease: a systematic review and meta-analysis of randomized controlled trials. BMC Cardiovasc Disord, 15, 2015, 96.
85. 85 Imazio, M., Adler, Y., Treatment with aspirin, NSAID, corticosteroids, and colchicine in acute and recurrent pericarditis. Heart Fail Rev 18 (2013), 355–360.
86. 86 Imazio, M., Brucato, A., Cumetti, D., et al. Corticosteroids for recurrent pericarditis: high versus low doses: a nonrandomized observation. Circulation 118 (2008), 667–671.
87. 87 Imazio, M., Brucato, A., Trinchero, R., et al. Corticosteroid therapy for pericarditis: a double-edged sword. Nat Clin Pract Cardiovasc Med 5 (2008), 118–119.
88. 88 Imazio, M., Lazaros, G., Brucato, A., et al. Recurrent pericarditis: new and emerging therapeutic options. Nat Rev Cardiol 13 (2016), 99–105.
89. 89 Vianello, F., Cinetto, F., Cavraro, M., et al. Azathioprine in isolated recurrent pericarditis: a single centre experience. Int J Cardiol 147 (2011), 477–478.
90. 90 Imazio, M., Lazaros, G., Picardi, E., et al. Intravenous human immunoglobulins for refractory recurrent pericarditis: a systematic review of all published cases. J Cardiovasc Med (Hagerstown) 17 (2016), 263–269.
91. 91 Moretti, M., Buiatti, A., Merlo, M., et al. Usefulness of high-dose intravenous human immunoglobulins treatment for refractory recurrent pericarditis. Am J Cardiol 112 (2013), 1493–1498.
92. 92 Picco, P., Brisca, G., Traverso, F., et al. Successful treatment of idiopathic recurrent pericarditis in children with interleukin-1β receptor antagonist (anakinra): an unrecognized autoinflammatory disease?. Arthritis Rheum 60 (2009), 264–268.
93. 93 Lazaros, G., Vasileiou, P., Koutsianas, C., et al. Anakinra for the management of resistant idiopathic recurrent pericarditis. Initial experience in 10 adult cases. Ann Rheum Dis 73 (2014), 2215–2217.
94. 94 Lazaros, G., Imazio, M., Brucato, A., et al. Anakinra: an emerging option for refractory idiopathic recurrent pericarditis: a systematic review of published evidence. J Cardiovasc Med (Hagerstown) 17 (2016), 256–262.
95. 95 Khandaker, M.H., Schaff, H.V., Greason, K.L., et al. Pericardiectomy vs medical management in patients with relapsing pericarditis. Mayo Clin Proc 87 (2012), 1062–1070.